Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Payables: 2020-2024

Historic Payables for Biofrontera (BFRI) over the last 5 years, with Dec 2024 value amounting to $4.3 million.

  • Biofrontera's Payables rose 40.77% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year decrease of 9.80%. This contributed to the annual value of $4.3 million for FY2024, which is 49.08% down from last year.
  • Per Biofrontera's latest filing, its Payables stood at $4.3 million for FY2024, which was down 49.08% from $8.4 million recorded in FY2023.
  • Biofrontera's Payables' 5-year high stood at $10.9 million during FY2022, with a 5-year trough of $2.7 million in FY2020.
  • For the 3-year period, Biofrontera's Payables averaged around $7.8 million, with its median value being $8.4 million (2023).
  • As far as peak fluctuations go, Biofrontera's Payables soared by 256.76% in 2021, and later slumped by 49.08% in 2024.
  • Yearly analysis of 5 years shows Biofrontera's Payables stood at $2.7 million in 2020, then surged by 256.76% to $9.7 million in 2021, then grew by 12.53% to $10.9 million in 2022, then declined by 22.76% to $8.4 million in 2023, then slumped by 49.08% to $4.3 million in 2024.